Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Icatibant in Healthy Japanese Volunteers
NCT02045264Phase 1Completed
- Sponsor
- Takeda
- Start
- Feb 2014
- Primary completion
- Feb 2014
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of icatibant in hereditary angioedema (HAE), sponsored by Takeda. Primary endpoints: Peak Plasma Concentration at 48 hours, Time to Peak Plasma Concentration at 48 hours and 4 more. Started Feb 2014; status: completed.
02
Drugs
icatibant
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NCT02045264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02045264.